Linifanib
Tocris Bioscience, part of Bio-Techne | Catalog # 7743
Potent inhibitor of PDGFRβ, KDR, FLT3 and CSF-1R
Key Product Details
Description
Potent inhibitor of PDGFRβ, KDR, FLT3 and CSF-1R
Product Description
Linifanib is a potent receptor tyrosine kinase (RTK) inhibitor. It inhibits PDGFRβ, KDR, FLT3, CSF-1R (IC50 values are 2, 4, 4 and 7 nM, respectively). Linifanib inhibits angiogenesis in vascularized micro-organs and potently inhibits VEGF-stimulated endothelial cell proliferation (IC50 = 0.2 nM). Linifanib also promotes the generation and reprogramming of iPSCs from somatic cells.Product Specifications
Molecular Weight
375.40
Formula
C21H18FN5O
Storage
Store at -20°C
Purity
≥98% (HPLC)
Chemical Name
N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea
CAS Number
796967-16-3
PubChem ID
11485656
InChI Key
MPVGZUGXCQEXTM-UHFFFAOYSA-N
SMILES
O=C(NC=1C=CC(=CC1)C=2C=CC=C3NN=C(N)C32)NC4=CC(=CC=C4F)C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 37.54 | 100 | |
| Ethanol | 7.51 | 20 |
Preparing Stock Solutions
for Linifanib
The following data is based on the product molecular weight 375.40
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.66 mL | 13.32 mL | 26.64 mL |
| 5 mM | 0.53 mL | 2.66 mL | 5.33 mL |
| 10 mM | 0.27 mL | 1.33 mL | 2.66 mL |
| 50 mM | 0.05 mL | 0.27 mL | 0.53 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Guan Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature 2022 PMID: 35418683
- Jahid Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer. Cell Rep. 2022 PMID: 35385746
- Albert Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol.Cancer Ther. 2006 PMID: 16648571
Product Specific Notices for Linifanib
For research use only
Loading...
Loading...